Garrido-MaraverJCorderoMDOropesa-AvilaMVegaAFde la MataMPavonADet al
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
Subsequently, cumulus-oocyte complexes (COCs) with a diameter of about 100130 m and a central oocyte surrounded by at least three layers of cumulus cells were collected according to the department's protocols ( After collection, COCs were transferred to 500 l of IVM droplets (4050 COCs per droplet) covered by mineral oil and cultured for a subsequent 24 h in a CO 2 incubator (38.5C and 5% CO 2 )
[2] mhra.gov.uk or via the Yellow Card app)
This is a long-term commitment, not a jump-start fad diet, she said
Age-Related Eye Disease Study Group
